NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02595008,Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis,https://clinicaltrials.gov/study/NCT02595008,,COMPLETED,this study is to evaluate the potential of DSXS to suppress HPA axis function in patients with moderate to severe atopic dermatitis.,YES,"Dermatitis, Atopic",DRUG: DSXS,"Number of Participants With HPA Axis Suppression, Hypothalamic Pituitary Adrenal (HPA) Axis Response to Cosyntropin demonstrating the absence or presence of adrenal suppression at the end of treatment. HPA Axis suppression is defined as a 30 minute post CortrosynTM injection level cortisol level of â‰¤ 18 mcg/100ml., 28 days.",,,Taro Pharmaceuticals USA,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,24,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,DSXS 1502,2015-08-28,2017-02-22,2017-08-25,2015-11-03,2018-11-12,2018-12-07,"Taro Pharmaceuticals USA Inc., Hawthorne, New York, 10532, United States","Study Protocol, https://storage.googleapis.com/ctgov2-large-docs/08/NCT02595008/Prot_000.pdf|Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/08/NCT02595008/SAP_001.pdf"
